HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call
TORONTO, Aug. 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2023 financial results on Thursday, August 10, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
CONFERENCE ID: 52567994
DATE: Thursday, August 10, 2023
TIME: 8:30 a.m. ET
WEBCAST LINK: https://app.webinar.net/Yd576N3ZzeW
TRADITIONAL DIAL-IN NUMBER: 1-888-664-6392 or 416-764-8659
RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3ND4vyc
TAPED REPLAY: 1-888-390-0541 or 416-764-8677
REPLAY CODE: 567994#
The taped replay will be available for 14 days and the archived webcast will be available for 365 days.
A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2023/03/c8132.html
